MI HB4878

Prohibits manufacturers, wholesalers, and wholesale distributor-brokers from denying, restricting, or discriminating against 340B entities or their contract pharmacies in acquiring or receiving 340B drugs

Requires manufacturers to report annually (starting July 1, 2026) on prescription drugs exceeding $40 per treatment course that had more than 15% wholesale acquisition cost increases, including production costs, patent expiration dates, and pricing history

Mandates that hospitals participating in the 340B program invest all savings into patient services or community benefit programs

Requires 340B hospital entities to submit annual reports (starting November 15, 2026) to a qualified hospital organization detailing drug acquisition costs, payments received, contract pharmacy payments, and community investment spending

Establishes civil fines of up to $500 per day for violations, with the Department of Licensing and Regulatory Affairs overseeing enforcement and the attorney general authorized to collect fines